Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design

Author:

Nooka Ajay K1ORCID,Weisel Katja2,van de Donk Niels WCJ3,Routledge David4,Otero Paula Rodriguez5,Song Kevin6,Quach Hang7,Callander Natalie8,Minnema Monique C9,Trudel Suzanne10,Jackson Nicola A11,Ahlers Christoph M12,Im Ellie13,Cheng Shinta14,Smith L14,Hareth Nahi15,Ferron-Brady Geraldine12,Brouch Maria12,Montes de Oca Rocio12,Paul Sofia12,Holkova Beata12,Gupta Ira12,Kremer Brandon E13,Richardson Paul16

Affiliation:

1. Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA

2. Department of Oncology, Hematology & Bone Marrow Transplantation, University Medical Center of Hamburg-Eppendorf, Hamburg, 20246, Germany

3. Department of Hematology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, 1081 HV, The Netherlands

4. Peter MacCallum Cancer Centre & Royal Melbourne Hospital, Melbourne, VIC 3000, Australia

5. Centro de Investigación Médica Aplicada, Clínica Universidad de Navarra-Pamplona, Navarra, 31008, Spain

6. Vancouver General Hospital, Vancouver, BC V5Z 1M9, Canada

7. Department of Haematology, University of Melbourne, St. Vincent’s Hospital Melbourne, Melbourne, VIC 3065, Australia

8. Carbone Cancer Center, University of Wisconsin, Madison, WI WI 53705, USA

9. Department of Hematology, University Medical Center Utrecht, Utrecht, 3584 CX, The Netherlands

10. Department of Medicine, Division of Medical Oncology & Hematology, Princess Margaret Cancer Centre, Toronto, ON M5G 2C1, Canada

11. GlaxoSmithKline, Stockley Park, UB11 1BT, UK

12. GlaxoSmithKline, Upper Providence, PA 19426, USA

13. GlaxoSmithKline, Waltham, MA 02451, USA

14. SpringWorks Therapeutics, Stamford, CT 06902, USA

15. Department of Medicine, Karolinska University Hospital, Stockholm, SE 171 76, Sweden

16. Department of Medical Oncology, Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA 02215, USA

Abstract

Belantamab mafodotin (belamaf) is a BCMA-targeted antibody–drug conjugate recently approved as monotherapy for adults with relapsed/refractory multiple myeloma who have received ≥4 prior therapies. Belamaf binds to BCMA and eliminates myeloma cells by multimodal mechanisms of action. The cytotoxic and potential immunomodulatory properties of belamaf have led to novel combination studies with other anticancer therapies. Here, we describe the rationale and design of DREAMM-5, an ongoing Phase I/II platform study evaluating the safety and efficacy of belamaf combined with novel agents, including GSK3174998 (OX40 agonist), feladilimab (an ICOS; GSK3359609), nirogacestat (a gamma-secretase inhibitor; PF-03084014) and dostarlimab (a PD-1 blocker) versus belamaf monotherapy for patients with relapsed/refractory multiple myeloma. Clinical trial registration: NCT04126200  (ClinicalTrials.gov).

Publisher

Future Medicine Ltd

Subject

Cancer Research,Oncology,General Medicine

Cited by 26 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3